What are the most common medicines used in medical Weight Loss? What is the difference between them?
The most common medications for medical weight loss are Semaglutide, Ozempic®, Rybelsus®, Wegovy®, Mounjaro®, and Trulicity®.
The primary differences between these GLP-1 medications such as Semaglutide, Ozempic®, Rybelsus®, and Wegovy® relate to the form of delivery. GLP-1 is a peptide hormone that is produced and released by the body when food is ingested and helps to reduce blood sugar levels in a glucose-dependent manner by promoting insulin secretion. For many years, drug formulations with GLP-1 have been successfully employed for treating type 2 diabetes,
yet nowadays they are also recognized for promoting weight loss whilst reducing the chance of hypoglycemia. Known effects on various organs and tissues include the heart, tongue, adipose tissue, muscles, bones, kidneys, liver, and lungs.
Semaglutide has been formally approved by the FDA for both diabetic patients in need of long-term glycemic control as well as for assisting new or existing customers to lose weight. Recent trials confirmed that a single course of this medication allowed people on average to 15% reduce their body fat percentage. While it could be utilized only once to discard unnecessary kilograms there exists an option to acquire regular prescriptions from trusted sources like Balanced Medical Solutions.
It no longer needs an immense fortune nor the celebrity status of people like Kim Kardashian or Elon Musk to take advantage of its incredible effectiveness – semaglutide can now be accessed conveniently through clinics similar to NuLife Medical at much more affordable prices than branded ones due to its generic form available through medical suppliers.
What sets semaglutide apart from other medications such as Mounjaro® (tirzepatide) and Trulicity® (dulaglutide)?
The primary contrast between semaglutide and its counterparts is that the FDA has not officially approved Mounjaro® and Trulicity® for medical weight loss in those who are not diabetic. Despite this, experiments show great potential with these GLP-1 receptor agonist drugs.
